Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Michael Benkowitz Biography and Net Worth

COO of United Therapeutics

Mr. Benkowitz joined United Therapeutics in 2011 as our Executive Vice President, Organizational Development, and was promoted to President and Chief Operating Officer in 2016.

He is responsible for all of our commercial, medical affairs, and corporate compliance activities, most company-wide administrative functions, including human resources and information technology, many of our business development efforts, and several of our key business alliances and partnerships.

What is Michael Benkowitz's net worth?: The estimated net worth of Michael Benkowitz is at least $926,637.66 as of November 25th, 2024. Mr. Benkowitz owns 2,577 shares of United Therapeutics stock worth more than $926,638 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Benkowitz may own. Additionally, Mr. Benkowitz receives a salary of $3,260,000.00 as COO at United Therapeutics. Learn More about Michael Benkowitz's net worth.
How old is Michael Benkowitz?: Mr. Benkowitz is currently 52 years old. There are 4 older executives and no younger executives at United Therapeutics. The oldest executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who is 69 years old. Learn More on Michael Benkowitz's age.
What is Michael Benkowitz's salary?: As the COO of United Therapeutics Co., Mr. Benkowitz earns $3,260,000.00 per year. The highest earning executive at United Therapeutics is Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO, who commands a salary of $5,660,000.00 per year. Learn More on Michael Benkowitz's salary.
How do I contact Michael Benkowitz?: The corporate mailing address for Mr. Benkowitz and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Michael Benkowitz's contact information.
Has Michael Benkowitz been buying or selling shares of United Therapeutics?: Within the last three months, Michael Benkowitz has sold $21,363,462.00 in shares of United Therapeutics stock. Most recently, Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a transaction totalling $3,727,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $960,576.75. Learn More on Michael Benkowitz's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 80 times. They sold a total of 472,479 shares worth more than $143,828,624.02. The most recent insider tranaction occured on December, 18th when Director Louis W Sullivan sold 26,209 shares worth more than $9,781,722.98. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 12/18/2024.

Michael Benkowitz Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2024	Sell	10,000	$372.75	$3,727,500.00	2,577
11/11/2024	Sell	15,000	$407.32	$6,109,800.00
11/7/2024	Sell	15,000	$401.44	$6,021,600.00	2,577
11/1/2024	Sell	14,700	$374.46	$5,504,562.00	2,577
8/7/2024	Sell	25,000	$323.38	$8,084,500.00	2,577

Michael Benkowitz Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $359.58

$357.98

$363.90

50 Day Range

MA: $371.01

$348.65

$410.00

2 Week Range

Now: $359.58

$208.62

$417.82

Volume

1,009,218 shs

Average Volume

449,066 shs

Market Capitalization

$16.05 billion

P/E Ratio

15.79

Dividend Yield

N/A

Beta

0.54

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.

Michael Benkowitz Biography and Net Worth

What is Michael Benkowitz's net worth?

How old is Michael Benkowitz?

What is Michael Benkowitz's salary?

How do I contact Michael Benkowitz?

Has Michael Benkowitz been buying or selling shares of United Therapeutics?

Who are United Therapeutics' active insiders?

Are insiders buying or selling shares of United Therapeutics?